Plaque

Research Demonstrates Old-Fashioned Toothbrush Performs Better than Modern Versions

Thursday, October 21, 2021 - 4:00pm

Older toothbrushes have a flat bristle design compared to todays versions which tend to be uneven.

Key Points: 
  • Older toothbrushes have a flat bristle design compared to todays versions which tend to be uneven.
  • Because the Sound Feelings brand toothbrush has the lowest wear index, it is more effective in removing plaque and preventing tooth decay for longer periods of time.
  • A bonus benefit is that the traditional flat, slim handles fit in wall toothbrush holders, while the newer brushes do not.
  • Sound Feelings toothbrushes are available from the Plain Toothbrush website www.plain-toothbrush.com as well as Amazon, eBay, and ToothbrushExpress.

Four Advisors from Mercer Advisors Named to the 2021 Forbes Top Next-Gen Wealth Advisors List

Wednesday, October 20, 2021 - 2:00pm

DENVER, Oct. 20, 2021 /PRNewswire-PRWeb/ --Mercer Advisors Inc. ("Mercer Advisors"), a national Registered Investment Adviser (RIA) firm, today announced that four senior wealth advisors were named to the Forbes Top Next-Gen Wealth Advisors list.

Key Points: 
  • DENVER, Oct. 20, 2021 /PRNewswire-PRWeb/ --Mercer Advisors Inc. ("Mercer Advisors"), a national Registered Investment Adviser (RIA) firm, today announced that four senior wealth advisors were named to the Forbes Top Next-Gen Wealth Advisors list.
  • *
    "We are thrilled to have several of our talented wealth advisors recognized by Forbes as emerging leaders in wealth management," said Dave Welling, CEO of Mercer Advisors.
  • The four advisors from Mercer Advisors named to the Forbes Top Next-Gen Wealth Advisors List include:
    Jessica Caruso, CFP - Senior Wealth Advisor and Senior Director in Northern California is focused on delivering comprehensive financial planning and leading the Bay Area wealth advisor team.
  • Mercer Advisors Insurance Services, LLC (MAIS) is a wholly owned subsidiary of Mercer Advisors Inc. Employees of Mercer Global Advisors serve as officers of MAIS.

Global Heart Hub launches program to put the spotlight on an 'Invisible Nation' living with ASCVD - the world's #1 killer

Tuesday, October 19, 2021 - 8:00am

GALWAY, Ireland, Oct. 19, 2021 /PRNewswire/ -- The Global Heart Hub is pleased to launch Invisible Nation, a program aimed to expose and respond to the realities of atherosclerotic cardiovascular disease (ASCVD) – a silent, chronic disease which affects 300 million people across the world. Working with a global network of heart patient organisations and heart patient advocates, and created in partnership with Novartis, Invisible Nation aims to engage with all the stakeholders in cardiovascular diseases.

Key Points: 
  • ASCVD is a leading cause of this global heart disease crisis and we cannot ignore it.
  • This is something close to my heart and I'm proud that Novartis is partnering with Global Heart Hub to enact change.
  • The Global Heart Hub is the first global non-profit organisation established to provide a voice for those affected by or living with cardiovascular disease.
  • After recognizing that the significant prevalence of ASCVD continues to be hidden in plain sight, the Global Heart Hub in collaboration with Novartis decided to create Invisible Nation.

Global Heart Hub launches program to put the spotlight on an 'Invisible Nation' living with ASCVD - the world's #1 killer

Tuesday, October 19, 2021 - 8:00am

GALWAY, Ireland, Oct. 19, 2021 /PRNewswire/ -- The Global Heart Hub is pleased to launch Invisible Nation, a program aimed to expose and respond to the realities of atherosclerotic cardiovascular disease (ASCVD) – a silent, chronic disease which affects 300 million people across the world. Working with a global network of heart patient organisations and heart patient advocates, and created in partnership with Novartis, Invisible Nation aims to engage with all the stakeholders in cardiovascular diseases.

Key Points: 
  • ASCVD is a leading cause of this global heart disease crisis and we cannot ignore it.
  • This is something close to my heart and I'm proud that Novartis is partnering with Global Heart Hub to enact change.
  • The Global Heart Hub is the first global non-profit organisation established to provide a voice for those affected by or living with cardiovascular disease.
  • After recognizing that the significant prevalence of ASCVD continues to be hidden in plain sight, the Global Heart Hub in collaboration with Novartis decided to create Invisible Nation.

Ductile Iron Pipe Research Association Welcomes Saint John, New Brunswick, to the Sesquicentennial Club in Recognition of Using Cast Iron Pipe Continuously for 150 Years

Monday, October 18, 2021 - 9:11pm

BIRMINGHAM, Ala., Oct. 18, 2021 /PRNewswire/ -- The Ductile Iron Pipe Research Association (DIPRA) welcomes the Canadian city of Saint John, New Brunswick into its Sesquicentennial Club recognizing the city for its continued use of a 150-year-old cast iron water pipe.

Key Points: 
  • BIRMINGHAM, Ala., Oct. 18, 2021 /PRNewswire/ -- The Ductile Iron Pipe Research Association (DIPRA) welcomes the Canadian city of Saint John, New Brunswick into its Sesquicentennial Club recognizing the city for its continued use of a 150-year-old cast iron water pipe.
  • Cast iron pipe was first installed in the City of Saint John in 1837 and continued to be installed until the 1960s.
  • The city now prefers to use Ductile iron pipe, the modern-day successor to cast iron, in its infrastructure projects.
  • "The durability of cast iron pipe and Ductile iron pipe is what the city of Saint John prefers the most," said Brent McGovern, Saint John Commissioner of Utilities and Infrastructure.

HeartFlow Announces Enrollment of First Two Patients in REVEALPLAQUE Trial

Thursday, October 14, 2021 - 1:00pm

It is clear, however, that coronary plaque is the driving force behind understanding a patients risk of having a heart attack, said Dr. Meckel, lead Principal Investigator for REVEALPLAQUE at Bryan Heart.

Key Points: 
  • It is clear, however, that coronary plaque is the driving force behind understanding a patients risk of having a heart attack, said Dr. Meckel, lead Principal Investigator for REVEALPLAQUE at Bryan Heart.
  • To be able to accurately and non-invasively understand a patients plaque burden would be game changing in physicians abilities to save a patients life from a heart attack.
  • The REVEALPLAQUE trial is planned to enroll 250 patients with stable coronary artery disease from approximately 15 sites across the U.S. and Japan.
  • The HeartFlow FFRct Analysis is commercially available in the United States, UK, Canada, Europe and Japan.

FOSOO Launched Stylish Eco-friendly APEX Metal Sonic Electric Toothbrush with 180-Day Battery Life

Wednesday, October 13, 2021 - 10:56am

FOSOO , a start-up company that strives to bring us innovative oral care products, has launched the APEX sonic electric toothbrush .

Key Points: 
  • FOSOO , a start-up company that strives to bring us innovative oral care products, has launched the APEX sonic electric toothbrush .
  • APEX sonic toothbrush helps to remove up to 10x more plaque and improve gum health up to 3x vs a manual toothbrush due to its unique sonic vibration motor.
  • View the full release here: https://www.businesswire.com/news/home/20211013005530/en/
    FOSOO Launched Stylish Eco-friendly APEX Metal Sonic Electric Toothbrush with 180-Day Battery Life (Photo: Business Wire)
    FOSOO is the first brand to use zinc alloy to make electric toothbrushes.
  • The company has other products like the compact LUX rechargeable sonic electric toothbrush and the NOV rechargeable sonic electric toothbrush with OLED screen.

Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting

Tuesday, October 12, 2021 - 5:32pm

As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

Key Points: 
  • As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
  • Cohorts 1-5 have been fully enrolled (13 patients) and cohort 6 is currently enrolling in the Phase 2 study.
  • The primary objective of the study is to assess safety and efficacy of AU-011 via SC administration for purposes of treating primary indeterminate lesions and choroidal melanoma.
  • Choroidal melanoma is the most common primary intraocular tumor in adults and develops in the uveal tract of the eye.

NEC C&C Foundation Awards 2021 C&C Prize

Tuesday, October 12, 2021 - 7:56am

Because Dr. Kunihiko Fukushima's achievements were far-sighted and of great magnitude, we believe he is a worthy recipient of the C&C Prize.

Key Points: 
  • Because Dr. Kunihiko Fukushima's achievements were far-sighted and of great magnitude, we believe he is a worthy recipient of the C&C Prize.
  • His tireless commitment to making the dream of autonomously functioning robots into a reality makes him a worthy recipient of the C&C Prize.
  • Each prize winner receives a certificate, a plaque, and a cash award (ten million yen per group).
  • For additional information, please visit The NEC C&C Foundation website at: https://www.candc.or.jp/en/index.html
    NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world."

Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting

Monday, October 11, 2021 - 9:45pm

Cohorts 1-5 have been fully enrolled (13 patients) and cohort 6 is currently enrolling in the Phase 2 study.

Key Points: 
  • Cohorts 1-5 have been fully enrolled (13 patients) and cohort 6 is currently enrolling in the Phase 2 study.
  • The primary objective of the study is to assess safety and efficacy of AU-011 via SC administration for purposes of treating primary indeterminate lesions and choroidal melanoma.
  • Choroidal melanoma is the most common primary intraocular tumor in adults and develops in the uveal tract of the eye.
  • AU-011 is a first-in-class virus-like drug conjugate (VDC) therapy in clinical development for the first line treatment of choroidal melanoma.